Singapore’s Biomedical Cluster: Lessons From Two Decades of Innovation And Manufacturing Policy

Since 2000, Singapore has managed to shift its positioning from a pharmaceutical manufacturing outpost to a location for biomedical activities across the whole innovation and manufacturing value chain. This has been supported by a coordinated, proactive and patient policy that prioritised access to funding, skilled people and infrastructure provision, underpinned by a supportive regulatory environment.

Read the full case study here.